[What is the Relevance of Various Previous Lesions of the Peripheral Nervous System to a Thalidomide Polyneuropathy?]

Overview

Journal Z Neurol

Specialty Neurology

Date 1971 Jan 1

PMID 4109629

Authors

G P Liebaldt

F BROSER

Affiliations

Soon will be listed here.

References

BROSER F, Hopf H, Hohl J . [Problems of permanent damage in Contergan polyneuropathy and other polyneuropathies or polyneuritides. Results of clinical and electromyographic follow ups]. Nervenarzt. 1969; 40(1):33-5. View

KRUCKE W, von Hartrott H, Schroder J, Thomas E, Gibbels E, Scheid W . [Light and electron microscopic studies of late stages of thalidomide polyneuropathy]. Fortschr Neurol Psychiatr Grenzgeb. 1971; 39(1):15-50. View

Cohen S . Thalidomide polyneuropathy. N Engl J Med. 1962; 266:1268. DOI: 10.1056/NEJM196206142662409. View

Scheid W . About the damage caused by triorthocresyl phosphate. Nervenarzt. 2010; 18(2):56-66. View

Schumacher H, Smith R, Williams R . The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother. 1965; 25(2):338-51. PMC: 1510729. DOI: 10.1111/j.1476-5381.1965.tb02054.x. View

Frenkel H . [Contergan--side effects. Central nervous system manifestations and polyneuritic symptoms in long-term medication with N-phthalyl glutamic acid imide]. Med Welt. 1961; 18:970-5. View

STAEMMLER M, Lagler F . [Experimental animal studies on the question of thalidomide and nerve damage]. Arzneimittelforschung. 1965; 15(5):504-8. View

SHESKIN J . THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS. Clin Pharmacol Ther. 1965; 6:303-6. DOI: 10.1002/cpt196563303. View

SEITELBERGER F . [Thalidomide polyneuropathy. Clinical bioptical studies]. Wien Klin Wochenschr. 1968; 80(3):41-3. View

10.

WIECK H . [Distribution of paralysis in polyneuritis]. Dtsch Z Nervenheilkd. 1951; 165(2):201-30. View

11.

Michaelis R, TARNOW G . [NEUROLOGICAL DISEASES AS SEQUELS TO CONTERGAN USE IN DISORDERS OF INTESTINAL RESORPTION]. Nervenarzt. 1963; 34:129-31. View

12.

RAUEN H . [ARE THALIDOMIDE AND ITS BIOLOGICAL METABOLITES ANTAGONISTS OF GLUTAMIC ACID?]. Arzneimittelforschung. 1964; 14:111-5. View

13.

Smith R, Williams R, Williams R . Phthaloylisoglutamine, a metabolite of thalidomide. Life Sci (1962). 1962; 1:333-6. DOI: 10.1016/0024-3205(62)90128-5. View

14.

Gibbels E . [Toxic injuries in thalidomide medication]. Fortschr Neurol Psychiatr Grenzgeb. 1967; 35(8):393-411. View

15.

Becker J . [Polyneuritis due to contergan]. Nervenarzt. 1961; 32:321-3. View

16.

SKRE H . [THALIDOMIDE POLYNEURITIS: A FORM OF RIBOFLAVIN AVITAMINOSIS?]. Nord Med. 1963; 70:916-8. View

17.

Gibbels E . [Differential diagnosis of polyneuritides]. Nervenarzt. 1969; 40(10):470-5. View

18.

OSTERLOH G, Lagler F . [On the tolerability of N-phthalimidoglutarimide. Animal experimental studies on tolerance in long-term application of high doses]. Arzneimittelforschung. 1960; 10:985-7. View

19.

FLOERSHEIM G . Another chance for thalidomide. Lancet. 1966; 1(7430):207. DOI: 10.1016/s0140-6736(66)90738-0. View

20.

Passarge C, WIECK H . [Polyneuritis due to thallium]. Fortschr Neurol Psychiatr Grenzgeb. 1965; 33(9):477-557. View